ALTライブシグナル | Getagraph.comで利益を最大化

売る 34358 min ago

@ $9.09

発行日: 6 4月 2024 @ 05:00

リターン: -26.83%

前回のシグナル: 4月 5 - 03:18

前回のシグナル: 買う

リターン: -0.66 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:38):

Stats
本日の出来高	2.10M
平均出来高	4.65M
時価総額	471.52M
EPS	$0 ( 2024-03-27 )
次の収益日	( $-0.360 ) 2024-05-09
Last Dividend	$873.01 ( 2017-01-20 )
Next Dividend	$0 ( N/A )
P/E	-4.01
ATR14	$0.0180 (0.27%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-02	Roberts M Scot	Buy	7 775	Common Stock, par value $0.0001
2024-02-02	Roberts M Scot	Sell	2 330	Common Stock, par value $0.0001
2024-02-01	Roberts M Scot	Buy	6 166	Common Stock, par value $0.0001
2024-02-01	Roberts M Scot	Sell	1 801	Common Stock, par value $0.0001
2024-02-02	Roberts M Scot	Sell	7 775	Restricted Stock Units

INSIDER POWER
81.81
Last 99 transactions
Buy: 2 849 671 \| Sell: 279 919

ボリューム相関

長: -0.38 (neutral)

短: -0.49 (neutral)

Signal:(58.939) Neutral

Altimmune Inc 相関

10 最も正の相関
EBET	0.973
APEI	0.968
STRM	0.966
SY	0.964
ENTA	0.963
IMBI	0.963
CASA	0.958
SISI	0.958
CAMP	0.957
NSTG	0.957

10 最も負の相関
LDHA	-0.979
JUGG	-0.979
ADAL	-0.978
CRZN	-0.977
HORI	-0.976
AHRN	-0.974
AGGR	-0.974
TBSA	-0.974
HCNE	-0.973
LEGA	-0.973

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Altimmune Inc 相関 - 通貨/商品

0.00
( neutral )

0.07
( neutral )

0.00
( neutral )

-0.37
( neutral )

0.75
( moderate )

0.48
( neutral )

Altimmune Inc 財務諸表

Annual	2023
収益:	$426 000
総利益:	$-51 000.00 (-11.97 %)
EPS:	$-1.660

FY	2023
収益:	$426 000
総利益:	$-51 000.00 (-11.97 %)
EPS:	$-1.660

FY	2022
収益:	$-68 000.00
総利益:	$-136 000 (200.00 %)
EPS:	$-1.810

FY	2021
収益:	$4 410.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.00379

Financial Reports:

No articles found.

Altimmune Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Altimmune Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$873.01	2017-01-20
Last Dividend	$873.01	2017-01-20
Next Dividend	$0	N/A
Payout Date	2017-02-03
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$873.01	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-29)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2017	$873.01	655.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-203.67	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.412	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-0.510	1.500	-6.78	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	17.25	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	16.69	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	11.13	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00319	-1.500	9.95	-10.00	[0 - 0.6]
interestCoverageTTM	3 630.87	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	-1.297	2.00	-0.432	-0.865	[0 - 30]
freeCashFlowPerShareTTM	-1.298	2.00	-0.649	-1.298	[0 - 20]
debtEquityRatioTTM	0.00346	-1.500	9.99	-10.00	[0 - 2.5]
grossProfitMarginTTM	-76.88	1.000	-10.00	-10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-196.03	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-112.98	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.00202	0.800	-3.32	-2.66	[0.5 - 2]
Total Score				-0.982

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-4.89	1.000	-0.595	0	[1 - 100]
returnOnEquityTTM	-0.510	2.50	-4.36	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.298	2.00	-0.433	-1.298	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-1.297	2.00	-0.432	-0.865	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.0709	1.500	-3.81	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-177.96	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.80

Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.